Vaishali Pharma Share Price

7.720.27 (3.63%)

NSE

Closed
As On: 18 Jun, 2026, 03:29 PM IST
As On:

Sector: Pharmaceuticals
Industry: Pharma - Indian

STOCK SCORE

Unlock Scores

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Try ETMarkets GPTNEW

Open	7.60
High	7.80
Low	7.40
Prev Close	7.45
Volume	1,91,731
VWAP(₹)	7.65

Share Price	Value
Today/Current/Last	7.72-
Previous Day	7.45-

Vaishali Pharma Share Recommendations

No Recommendations details available for this stock.
Check out other stock recos.

News & Analysis

View all Vaishali Pharma Share News & Announcements

Share Analysis

EARNINGS

FUNDAMENTAL

RELATIVE VALUATION

RISK

PRICE MOMENTUM

Unlock Stock Score, Analyst' Ratings & Recommendations

Score on 10-point scale
Ratings by analysts
Stock performance

JOIN ET PRIME

Financials

Income (P&L)

	Mar 2026	Dec 2025	Sep 2025
Total Income	28.19	25.54	34.29
Total Income Growth (%)	10.36	-25.50	39.43
Total Expenses	27.29	23.22	32.23
Total Expenses Growth (%)	17.53	-27.95	43.10
EBIT	0.90	2.32	2.06
EBIT Growth (%)	-61.26	13.00	-0.52
Profit after Tax (PAT)	0.38	1.32	1.19
PAT Growth (%)	-71.08	11.07	-7.25
EBIT Margin (%)	3.19	9.10	6.00
Net Profit Margin (%)	1.35	5.16	3.46
Basic EPS (₹)	0.03	0.10	0.09

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	28.19	25.54	34.29	24.59	33.25
Total Income Growth (%)	10.36	-25.50	39.43	-26.05	14.73
Total Expenses	27.29	23.22	32.23	22.52	38.41
Total Expenses Growth (%)	17.53	-27.95	43.10	-41.36	44.02
EBIT	0.90	2.32	2.06	2.07	-5.16
EBIT Growth (%)	-61.26	12.99	-0.52	-	-323.19
Profit after Tax (PAT)	0.27	1.30	1.18	1.28	-4.29
PAT Growth (%)	-79.52	9.85	-7.40	-	-397.56
EBIT Margin (%)	3.19	9.10	6.00	8.41	-15.52
Net Profit Margin (%)	0.95	5.09	3.46	5.20	-12.91
Basic EPS (₹)	0.02	0.10	0.49	0.10	-3.17

	FY 2026
Total Revenue	112.61
Total Revenue Growth (%)	-
Total Expenses	107.22
Total Expenses Growth (%)	-
Profit after Tax (PAT)	4.16
PAT Growth (%)	-
Operating Profit Margin (%)	6.75
Net Profit Margin (%)	3.82
Basic EPS (₹)	0.32

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	112.61	102.23	88.31	71.89	77.61
Total Revenue Growth (%)	10.15	15.76	22.84	-7.37	39.63
Total Expenses	107.22	101.01	87.39	63.05	71.88
Total Expenses Growth (%)	6.15	15.58	38.61	-12.29	32.67
Profit after Tax (PAT)	4.03	0.82	0.72	6.60	4.02
PAT Growth (%)	393.21	13.70	-89.11	64.12	284.58
Operating Profit Margin (%)	6.75	2.83	3.08	15.58	10.79
Net Profit Margin (%)	3.70	0.82	0.83	9.47	5.30
Basic EPS (₹)	0.31	0.06	0.68	6.26	3.82

All figures in Rs Cr, unless mentioned otherwise

Insights

Employee & Interest Expense
Company has spent 1.8% of its operating revenues towards interest expenses and 2.68% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)

View Details

Balance Sheet

Annual	FY 2026
Total Assets	123.39
Total Assets Growth (%)	-
Total Liabilities	54.27
Total Liabilities Growth (%)	-
Total Equity	69.12
Total Equity Growth (%)	-
Current Ratio (x)	2.34
Total Debt to Equity (x)	0.27
Contingent Liabilities	0.00

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	123.26	109.84	79.96	78.90	81.62
Total Assets Growth (%)	12.22	37.37	1.34	-3.33	-5.23
Total Liabilities	54.27	44.93	37.12	38.37	55.27
Total Liabilities Growth (%)	20.79	21.04	-3.26	-30.58	-13.23
Total Equity	68.99	64.92	42.84	40.53	26.35
Total Equity Growth (%)	6.27	51.54	5.70	53.81	17.53
Current Ratio (x)	2.34	2.61	2.25	2.27	1.47
Total Debt to Equity (x)	0.27	0.18	0.35	0.41	0.79
Contingent Liabilities	0.00	-	-	-	-

All figures in Rs Cr, unless mentioned otherwise

View Details

Cash Flows

Annual	FY 2026
Net Cash flow from Operating Activities	-
Net Cash used in Investing Activities	-
Net Cash flow from Financing Activities	-
Net Cash Flow	-
Closing Cash & Cash Equivalent	-
Closing Cash & Cash Equivalent Growth (%)	-
Total Debt/ CFO (x)	-

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	0.31	-18.04	0.81	1.08	1.32
Net Cash used in Investing Activities	-5.33	-0.19	1.20	0.28	-0.85
Net Cash flow from Financing Activities	4.61	18.49	-1.42	-1.73	0.42
Net Cash Flow	-0.41	0.26	0.59	-0.37	0.89
Closing Cash & Cash Equivalent	1.43	1.84	1.58	0.98	1.36
Closing Cash & Cash Equivalent Growth (%)	-22.40	16.77	60.28	-27.34	190.83
Total Debt/ CFO (x)	60.61	-0.65	15.63	12.66	15.75

All figures in Rs Cr, unless mentioned otherwise

Insights

Increase in Cash from Investing
Company has used Rs 5.33 cr for investing activities which is an YoY increase of 2733.65%. (Source: Standalone Financials)

View Details

Ratios

Annual	FY 2026
Return on Equity (%)	6.02
Return on Capital Employed (%)	9.78
Return on Assets (%)	3.37
Interest Coverage Ratio (x)	4.05
Asset Turnover Ratio (x)	-
Price to Earnings (x)	15.29
Price to Book (x)	0.92
EV/EBITDA (x)	10.16
EBITDA Margin (%)	7.30

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	5.84	1.25	2.00	20.02	15.26
Return on Capital Employed (%)	9.80	4.02	5.68	23.17	27.57
Return on Assets (%)	3.27	0.74	0.89	8.36	4.92
Interest Coverage Ratio (x)	4.05	2.08	1.83	5.66	3.52
Asset Turnover Ratio (x)	0.93	1.04	1.09	0.87	0.90
Price to Earnings (x)	15.80	204.08	212.77	23.31	17.36
Price to Book (x)	0.92	2.53	4.19	4.67	2.65
EV/EBITDA (x)	10.16	52.78	50.82	14.66	10.32
EBITDA Margin (%)	7.30	3.32	3.67	16.30	11.39

Found Financials useful?

5 Days	14 Days	28 Days
-	-	-

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Vaishali Pharma	24.03	1.45	6.02	9.78	3.37	15.96	6.75	3.70	0.32	2.34	0.27	0.00
Brooks Labs	8.15	1.63	20.04	5.25	16.59	10.96	7.74	6.77	8.35	1.72	0.06	0.78
Natural Capsule	-7.14	0.70	-7.70	-5.82	-4.02	2.96	-9.06	-13.17	-23.84	1.03	0.52	10.47
Alpa Labs	10.00	0.77	7.58	8.94	5.83	5.85	16.02	13.35	6.71	4.01	0.01	0.24
Bal Pharma	22.24	1.70	7.68	18.01	1.68	0.90	7.30	2.02	3.95	1.05	1.94	20.28
Add More

Annual Ratios (%)

Choose from Peers

Krebs Biochem
Par Drugs & Chemical
Biofil Chem
Vivimed Labs
Mangalam Drugs

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

NAME	1D	1W	1M	3M	1Y	3Y	5Y
Vaishali Pharma Stock Performance	3.63	11.08	-14.88	-0.13	-39.92	-41.91	106.97
Brooks Labs Stock Performance	1.54	41.67	6.18	-8.69	-50.16	9.06	-29.24
Natural Capsule Stock Performance	4.75	1.99	-1.07	0.59	-20.07	0.00	0.00
Alpa Labs Stock Performance	-2.56	-0.50	-1.35	1.42	-36.59	15.41	20.11
Bal Pharma Stock Performance	-0.21	11.20	13.15	12.80	-11.51	3.46	-8.93
Add More

Category	No. of Shares	Percentage
Promoters	4,12,35,290	31.61 %
Pledge	0	0.00 %
FII	968	0.00 %
Others	8,92,25,872	68.39 %

Category	Mar 2026	Dec 2025	Sep 2025	Jun 2025
Promoters	31.61	31.61	26.32	26.32
Pledge	0.00	0.00	0.00	0.00
FII	0.00	0.00	0.00	0.00
DII	0.00	0.00	0.00	0.00
Mutual Funds	0.00	0.00	0.00	0.00
Others	68.39	68.39	73.68	73.68

Mutual Funds Ownership

No Data Available

Corporate Actions

Recent
Board Meeting
Audited Results & Others
May 26, 2026
Board Meeting
Quarterly Results & Others
Feb 10, 2026
Board Meeting
Quarterly Results
Nov 10, 2025

Board Meetings

Announced on	Meeting on
May 26, 2026	May 30, 2026
Audited Results & Others
Feb 10, 2026	Feb 13, 2026
Quarterly Results & Others
Nov 10, 2025	Nov 14, 2025
Quarterly Results
Aug 08, 2025	Aug 11, 2025
Quarterly Results & Others
May 26, 2025	May 28, 2025
Audited Results & Others

Dividends
No Data Available
Bonus
Announced on Ex-Date
Aug 28, 2024 Oct 15, 2024
Bonus Ratio: 1 share(s) for every 1 shares held
Aug 26, 2019 Oct 17, 2019
Bonus Ratio: 3 share(s) for every 5 shares held
Splits
Announced on Ex-Date
Aug 28, 2024 Oct 15, 2024
Split: Old FV10.0| New FV:2.0
Rights
No Data Available

Announced on	Ex-Date
Aug 28, 2024	Oct 15, 2024
Bonus Ratio: 1 share(s) for every 1 shares held
Aug 26, 2019	Oct 17, 2019
Bonus Ratio: 3 share(s) for every 5 shares held

Announced on	Ex-Date
Aug 28, 2024	Oct 15, 2024
Split: Old FV10.0\| New FV:2.0

AGM/EGM Meetings

Announced on	Meeting on
Aug 09, 2024	Sep 27, 2024
Book closure from Sep 20, 2024 to Sep 27, 2024
Aug 12, 2023	Sep 29, 2023
Annual General Meeting
Sep 07, 2018	Sep 29, 2018
Book closure from Sep 21, 2018 to Sep 29, 2018

About Vaishali Pharma

Vaishali Pharma Ltd., incorporated in the year 2008, is a Small Cap company (having a market cap of Rs 100.06 Crore) operating in Pharmaceuticals sector.

Vaishali Pharma Ltd. key Products/Revenue Segments include Pharmaceutical Products, Commission and Export Incentives for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 28.19 Crore, up 10.36 % from last quarter Total Income of Rs 25.54 Crore and unchanged .00 % from last year same quarter Total Income of Rs Crore. Company has reported net profit after tax of Rs .27 Crore in latest quarter.

The company’s top management includes Mr.Atul Arvind Vasani, Mr.Hemanth Damodar Pathak, Mr.Dewansh Ajay Vasani, Mrs.Jagruti Atul Vasani, Mr.Bhaveshkumar Upadhyay, Mr.Manish Bhagwandas Ved, Mr.Pratik Vikram Jakhelia, Ms.Vishwa Mekhia. Company has Raman S Shah & Associates as its auditors. As on 31-03-2026, the company has a total of 13.05 Crore shares outstanding.

Vaishali Pharma Share Price Today is Rs. 7.72. On previous day, the Vaishali Pharma Share Price (NSE) closed at Rs. 7.16, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 31.61% of the stake in Vaishali Pharma shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Vaishali Pharma stocks was 0.0% as compared to 0.0% in Dec 2025 with decrease of 0.0%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 0.0% as compared to 0.0% in Dec 2025 with decrease of 0.0%. Out of the total DII holdings in Vaishali Pharma shares 0.0% was held by mutual funds. The rest including public held is 68.39%. Vaishali Pharma stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Vaishali Pharma Dividend: Ever since 2008, Vaishali Pharma dividends has been paid out around 0 times. As on 18 Jun, 2026, 03:29 PM IST, The overall dividend yield for Vaishali Pharma stands at 0.0%. The last dividend paid was on null (Rs. null). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 0.32.

Vaishali Pharma Bonus: The most recent bonus issue had been in year October 15, 2024 around 1 years ago at 1 : 1 ratio. The first bonus issue was announced in Aug 2019.

Stock Forecast:
After showing 28.19 Cr. of sales and 10.36% of quarterly net profit, there have been multiple ups and downs in the Vaishali Pharma stock prices in the past few weeks. For example, Vaishali Pharma stock price on 10th of June 2026 was around Rs. 7.13. Vaishali Pharma share price now stands at an average of Rs. 7.72. Judging by last week's performance, stock is in up trend.

Vaishali Pharma has a median target price of Rs. 0.0 in 12 months by 0 analysts. They have provided a high estimate of Rs. 0.0 and low estimate of Rs. 0.0 for Vaishali Pharma share.

Historical Prices and Performance:
Vaishali Pharma, incorporated in 2008 is a Small Cap company (with a market cap of Rs. 97.19) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Vaishali Pharma stock was 6.02%, 1.25%, 2.0%, 20.02% and 15.26% respectively.
The Vaishali Pharma share gave a 3 year return of -41.59% as compared to Nifty 50 which gave a return of 27.94%.
Vaishali Pharma announced 0.0% final dividend on null.

Key Metrics:
PE Ratio of Vaishali Pharma is 23.34
Prices/Sales Ratio of Vaishali Pharma is 0.59
Price/Book Ratio of Vaishali Pharma is 1.41

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Vaishali Pharma, major competitors and peers include Brooks Labs, Natural Capsule, Alpa Labs and Bal Pharma. As of Dec 2025, the dividend yield of Vaishali Pharma stands at 0.0% while Brooks Labs, Natural Capsule, Alpa Labs and Bal Pharma stand at 0.0%, 0.0%, 0.0% and 1.36% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 23.34 and 1.41 respectively.

Leadership of Vaishali Pharma :
Vishwa Mekhia is Co. Secretary & Compl. Officer
Hemanth Damodar Pathak is Chief Executive Officer
Atul Arvind Vasani is Chairman & Managing Director
Dewansh Ajay Vasani is Executive Director & CFO
Jagruti Atul Vasani is Whole Time Director
Manish Bhagwandas Ved is Ind. Non-Executive Director
Pratik Vikram Jakhelia is Ind. Non-Executive Director
Bhaveshkumar Upadhyay is Non Exe.Non Ind.Director

Industry

Pharma - Indian

Key Indices Listed On

-

Address

706 to 709, 7th Floor,Aravali Business Center,R. C. Patel Road,Mumbai, Maharashtra - 400092

Contact

cs@vaishalipharma.com

http://www.vaishalipharma.com

PE Ratio(x)	24.03
EPS - TTM(₹)	0.32
MCap(₹ Cr.)	100.06
MCap Rank	112
PB Ratio(x)	1.41
Div Yield(%)	-
Face Value(₹)	2.00
52W High(₹)	13.59
52W Low(₹)	4.75
MCap/Sales	0.59
Beta(1 Month)	-0.03
BV/Share(₹)	5.30

1 Day	3.63%
1 Month	12.37%
3 Months	25.94%
1 Year	-37.74%
3 Years	-39.47%
5 Years	97.95%

R1	-	Pivot -	S1	-
R2	-		S2	-
R3	-		S3	-

Vaishali Pharma Share Price

Key Metrics